1
2
3
*Corresponding Author E-mail: waghasuresh@gmail.com
Recent advancements in polymeric microparticle-based drug delivery systems offer a transformative approach to addressing the global health challenge of diabetes mellitus. With millions affected worldwide, especially in low- and middle-income countries, conventional treatments often fall short in efficacy, adherence, and minimizing systemic side effects. However, innovative drug delivery systems herald a paradigm shift in diabetes management. Polymeric microparticles provide a versatile platform with controlled drug release, targeted delivery, enhanced stability, and improved bioavailability. Choosing natural, synthetic, hybrid, or responsive polymers influences crucial properties like release kinetics and biocompatibility. Different preparation techniques, such as microfluidics and emulsion solvent evaporation, enable customized particle properties. Innovative strategies such as targeted delivery, sustained-release formulations, and combination therapies promise improved outcomes for diabetes patients. Polymeric microparticles can improve glycemic control; recent clinical trials have confirmed this. Looking forward, technologies like closed-loop artificial pancreas systems and precision medicine offer personalized and optimized care, paving the way for better management and potentially, the prevention and cure of diabetes mellitus. Through these advancements, researchers and clinicians aim to revolutionize diabetes treatment, alleviating its global burden on individuals and healthcare systems.
Diabetes, Microparticles, Polymers, Clinical Trials